Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation

Clinical Pharmacokinetics

Volumn 53, Issue 3, 2014, Pages 247-259

  Vélez De Mendizábal, Nieves ^a,b   Strother, Robert M ^a,c   Farag, Sherif S ^a   Broxmeyer, Hal E ^a   Messina Graham, Steven ^a   Chitnis, Shripad D ^a,b   Bies, Robert R ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Indiana Clinical and Translational Sciences Institute (CTSI)   (United States)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DIPEPTIDYL PEPTIDASE IV; FLUDARABINE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SITAGLIPTIN; TACROLIMUS; THYMOCYTE ANTIBODY; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMPARTMENT MODEL; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; MULTIPLE DRUG DOSE; MYELOABLATIVE CONDITIONING; NEGATIVE FEEDBACK; OPTIMAL DRUG DOSE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RADIOTHERAPY; SIMULATION; WHOLE BODY RADIATION; BLOOD; DOSE RESPONSE; ENZYMOLOGY; HEMATOLOGIC NEOPLASMS; METABOLISM; POPULATION;

AREA UNDER CURVE; CORD BLOOD STEM CELL TRANSPLANTATION; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOLOGIC NEOPLASMS; HUMANS; POPULATION; PYRAZINES; TRIAZOLES;

EID: 84896815490     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0109-y     Document Type: Article

References (37)

1. Neumiller JJ. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther. 2011;33(5):528-76.
2. Christopherson KW 2nd, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol. 2002;169(12):7000-8. (Pubitemid 36899288)
3. Broxmeyer HE, Cooper S, Kohli L, Hangoc G, Lee Y, Mantel C, et al. Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol. 2003;170(1):421-9. (Pubitemid 36026167)
4. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283(5403):845-8.
5. Broxmeyer HE, Hoggatt J, O'Leary HA, Mantel C, Chitteti BR, Cooper S, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med. 2012;18(12):1786-96.
6. Brunstein CG, Setubal DC, Wagner JE. Expanding the role of umbilical cord blood transplantation. Br J Haematol. 2007;137(1):20-35. (Pubitemid 46426403)
7. Rocha V, Broxmeyer HE. New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S126-32.
8. Broxmeyer HE, Farag SS, Rocha V. Cord blood hematopoietic cell transplantation. In: Thomas' hematopoietic cell transplantation. New York: Wiley-Blackwell; 2013.
9. Farag SS, Srivastava S, Messina-Graham S, Schwartz J, Robertson MJ, Abonour R, et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev. 2013;22(7):1007-15.
10. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28(1):55-72. (Pubitemid 43254990)
11. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675-88. (Pubitemid 41773643)
12. Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos. 2007;35(4):533-8. (Pubitemid 46513255)
13. Kim BH, Kim SE, Kang D, Lim KS, Kim JR, Jang IJ, et al. Pharmacokinetic-pharmacodynamic modeling of biomarker response to sitagliptin in healthy volunteers. Basic Clin Pharmacol Toxicol. 2013;113(2):113-25.
14. Herman GA, Mistry GC, Yi B, Bergman AJ, Wang AQ, Zeng W, et al. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. Br J Clin Pharmacol. 2011;71(3):429-36.
15. Bergman A, Mistry GC, Luo WL, Liu Q, Stone J, Wang A, et al. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. 2007;28(6):307-13. (Pubitemid 47439636)
16. Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46(8):876-86. (Pubitemid 44050824)
17. Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. 2007;28(6):315-22. (Pubitemid 47439637)
18. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24(12):2187-97. (Pubitemid 350060706)
19. Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike information criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm. 1994;22(5):431-45.
20. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85-94. (Pubitemid 38798039)
21. Ou X, O'Leary H, Broxmeyer HE. Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Blood. 2013;122(2):161-9.
22. O'Leary H, Ou X, Broxmeyer HE. The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation. Curr Opin Hematol. 2013;20(4):314-9.
23. Christopherson KW 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004;305(5686):1000-3. (Pubitemid 39071774)
24. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337(6):373-81.
25. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339(22):1565-77. (Pubitemid 28536131)
26. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611-8. (Pubitemid 34925136)
27. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122(4):491-8.
28. Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2007;14(2):98-107. (Pubitemid 46363290)
29. Jacobson P, Uberti J, Davis W, Ratanatharathorn V. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998;22(3):217-25. (Pubitemid 28382985)
30. Jones RJ, Grochow LB. Pharmacology of bone marrow transplantation conditioning regimens. Ann N Y Acad Sci. 1995;29(770):237-41. (Pubitemid 26136301)
31. Nieto Y, Vaughan WP. Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant. 2004;33(3):259-69. (Pubitemid 38256557)
32. Przepiorka D, Devine S, Fay J, Uberti J, Wingard J. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. Bone Marrow Transplant. 1999;24(10):1053-6.
33. Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007;321(2):673-83. (Pubitemid 46624514)
34. Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol. 2007;47(2):165-74. (Pubitemid 46146482)
35. Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38(3):169-74. (Pubitemid 44102943)
36. Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ, et al. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos. 2007;35(4):525-32. (Pubitemid 46513254)
37. Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem. 2000;267(17):5608-13.